RNS & Investor News

Director Appointment

10 September 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):

Current Appointments Appointments in the last 5 years
ACCSYS Technologies Plc Croda Enterprises Limited
Applied Graphene Materials Plc Croda Europe Limited
Turner & Townsend Limited Croda International Plc
Croda Investments Limited
Croda Investments No 2 Limited
Croda JDH Limited
Croda Overseas Holdings Limited
Croda Polymers International Limited
Croda World Traders Limited
Eminate Limited
Produce Investments Limited

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive		 www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Jo Turner		 Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)		 Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Lianne Cawthorne		 Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07584 391 303

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.